Fresenius SE & Co KGaA (FRE.DE) Aktie Kurs
Fresenius SE & Co KGaA Kurs
Omsætningen er vokset med 4,0 % om året de seneste 19 år til 22,87 Mrd. EUR. Indtjening pr. aktie er vokset med 6,2 % om året de seneste 19 år. Fresenius SE & Co KGaAs nettoavance ligger på 5,5 %, overvejende stabil fra 4,9 % for flere år siden. Fresenius SE & Co KGaA har i øjeblikket et direkteafkast på omkring 2,05 %. Udlodningsandelen er omkring 45 % af indtjeningen. Udbyttet er vokset med 10,0 % om året de seneste 19 år. Analytikernes mediankursmål er 57,12 EUR, hvilket er over den aktuelle kurs med 17,1 %. Af 23 analytikere anbefaler 21 køb — den samlede vurdering er Køb.
Fresenius SE & Co KGaA aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Fresenius SE & Co KGaA aktie og aktieanalyse
Hyppigt stillede spørgsmål om Fresenius SE & Co KGaA-aktien
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 56,38 EUR for Fresenius SE & Co KGaA-aktien (median: 57,12 EUR), svarende til +15,6 % i forhold til seneste kurs. Konsensus bygger på 23 analytikervurderinger.
23 analytikere vurderer i øjeblikket Fresenius SE & Co KGaA-aktien: 21 anbefaler køb, 2 hold og 0 salg. For 2026 forventer analytikere, at Fresenius SE & Co KGaA genererer omsætning på 23,71 Mrd. EUR og indtjening pr. aktie på 3,63 EUR.
Fresenius SE & Co KGaA-aktien (FRE.DE) er noteret på 10 børser, herunder: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
forventet-omsætningen for Fresenius SE & Co KGaA er 23,71 Mrd. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Fresenius SE & Co KGaA er 2,05 Mrd. EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Fresenius SE & Co KGaA er i øjeblikket 13,43. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Fresenius SE & Co KGaA-aktien.
Pris-til-salgs-forholdet (P/S) for Fresenius SE & Co KGaA er i øjeblikket 1,16. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Fresenius SE & Co KGaA-aktien.
AlleAktien-kvalitetsscore for Fresenius SE & Co KGaA er 2/10.
ISIN for Fresenius SE & Co KGaA er DE0005785604. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Fresenius SE & Co KGaA er 578560. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Fresenius SE & Co KGaA er FRE.DE. Tickersymbolet bruges til at handle Fresenius SE & Co KGaA-aktier på børsen.
Fresenius SE & Co KGaA aktie
Fresenius SE & Co KGaA Peer Group
Fresenius SE & Co KGaA Ticker
Fresenius SE & Co KGaA FIGI
Alle fundamentale data om Fresenius SE & Co KGaA i deep dive
Vores aktieanalyse af Fresenius SE & Co KGaA-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Fresenius SE & Co KGaA. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: